Table 4.
The association between the genetic risk score and the risk of NAFLD
| GRS | Controls [n (%)] | NAFLD cases [n (%)] | Propensity score matching |
Inverse probability of treatment weighting |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| OR1 (95% CI) | P 1 | OR2 (95% CI) | P 2 | OR1 (95% CI) | P 1 | OR2 (95% CI) | P 2 | |||
| 0 | 17 (2.2) | 7 (0.9) | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – | 1 (reference) | – |
| 1 | 122 (15.9) | 108 (14.0) | 2.329 (0.876–6.197) | 0.090 | 3.696 (1.144–11.943) | 0.029 | 2.113 (1.111–4.021) | 0.023 | 3.487 (1.624–7.485) | 0.001 |
| ≥2 | 627 (81.9) | 657 (85.1) | 2.822 (1.096–7.269) | 0.032 | 3.851 (1.241–11.953) | 0.020 | 2.611 (1.403–4.861) | 0.002 | 3.778 (1.807–7.898) | <0.001 |
| P for trend | 0.026 | 0.137 | 0.001 | 0.012 | ||||||
OR1 adjusted for age and sex.
OR2 adjusted for age, sex, body mass index, hypertension, diabetes, serum total triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, alanine aminotransferase, aspartate aminotransferase, and the polymorphisms in the HFE2 gene.
NAFLD, non-alcoholic fatty liver disease; OR, odds ratio; CI, confidence interval; GRS, genetic risk score.